This is marketing material. Past performance is not a guarantee of future returns. Returns may be negative due to falling market values.
Future returns will depend, among other things, on market developments, the manager’s skill, the fund’s risk profile, and associated costs. Before investing, customers are advised to review the fund’s key information and prospectus, which contain more detailed information about the fund’s characteristics and costs. Note: Investing in the fund means acquiring units in the fund, not the underlying investments.
Healthcare and Biotech: Is a Turning Point Finally Here?
After several challenging years, the healthcare and biotech sectors may be poised for renewed momentum.
The healthcare and biotech sectors have faced several challenging years, but recent developments suggest the tide may be turning. In this webinar, Portfolio Manager Rune Sand-Holm joins Jørgen Mørk in our Oslo studio to discuss what has driven the sector’s renewed momentum, why sentiment may be shifting, and where they see the most attractive opportunities going into 2026. The conversation covers valuation levels, regulatory developments, innovation trends – including the role of artificial intelligence – and a closer look at both large‑cap and small‑ to mid‑cap segments.
This concise update provides timely insights into a sector that may be poised for a stronger year ahead.
Go to the fund-page for more information:
DNB Fund Health Care
Invest in a sector with stability, innovation, and global significance.
